Athenex Inc (NASDAQ:ATNX) CEO Johnson Yiu Nam Lau bought 12,000 shares of Athenex stock in a transaction on Friday, March 15th. The stock was acquired at an average price of $11.77 per share, for a total transaction of $141,240.00. Following the purchase, the chief executive officer now owns 2,932,236 shares of the company’s stock, valued at $34,512,417.72. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.
Johnson Yiu Nam Lau also recently made the following trade(s):
- On Monday, March 11th, Johnson Yiu Nam Lau bought 10,000 shares of Athenex stock. The stock was acquired at an average price of $11.78 per share, for a total transaction of $117,800.00.
Shares of Athenex stock traded up $0.48 during trading on Friday, hitting $11.87. 475,120 shares of the stock traded hands, compared to its average volume of 248,671. The firm has a market cap of $792.89 million, a P/E ratio of -8.24 and a beta of 0.23. The company has a current ratio of 3.31, a quick ratio of 3.86 and a debt-to-equity ratio of 0.36. Athenex Inc has a 52-week low of $9.83 and a 52-week high of $20.90.
Several institutional investors have recently made changes to their positions in the company. Perceptive Advisors LLC increased its stake in shares of Athenex by 77.6% during the fourth quarter. Perceptive Advisors LLC now owns 5,096,022 shares of the company’s stock valued at $32,550,000 after buying an additional 2,226,494 shares during the period. BlackRock Inc. grew its stake in Athenex by 0.9% in the fourth quarter. BlackRock Inc. now owns 3,616,333 shares of the company’s stock valued at $45,892,000 after purchasing an additional 33,755 shares during the last quarter. Vanguard Group Inc grew its stake in Athenex by 8.3% in the third quarter. Vanguard Group Inc now owns 1,878,063 shares of the company’s stock valued at $29,185,000 after purchasing an additional 144,410 shares during the last quarter. Vanguard Group Inc. grew its stake in Athenex by 8.3% in the third quarter. Vanguard Group Inc. now owns 1,878,063 shares of the company’s stock valued at $29,185,000 after purchasing an additional 144,410 shares during the last quarter. Finally, Geode Capital Management LLC grew its stake in Athenex by 7.7% in the fourth quarter. Geode Capital Management LLC now owns 489,666 shares of the company’s stock valued at $6,213,000 after purchasing an additional 35,061 shares during the last quarter. Hedge funds and other institutional investors own 31.81% of the company’s stock.
A number of analysts have weighed in on the company. BidaskClub lowered Athenex from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Royal Bank of Canada restated an “outperform” rating on shares of Athenex in a research note on Tuesday. Finally, JPMorgan Chase & Co. upgraded Athenex from a “neutral” rating to an “overweight” rating and cut their price target for the company from $24.00 to $15.00 in a research note on Thursday, November 15th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $20.00.
COPYRIGHT VIOLATION NOTICE: This report was published by WKRB News and is the sole property of of WKRB News. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://www.wkrb13.com/2019/03/15/athenex-inc-atnx-ceo-johnson-yiu-nam-lau-acquires-12000-shares.html.
Athenex Company Profile
Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer.
Read More: What is Call Option Volume?
Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.